Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Novel Causal Inference Method Estimates Treatment Effects of Contemporary Drugs in a Global Cohort of Patients with Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms

Blood (2023) 142 (Supplement 1): 1703.

https://doi.org/10.1182/blood-2023-185881

Published: 2023

Journal Articles

Impact of Therapy Sequence on Survival Outcomes Among Patients with Relapsed or Refractory Mature T and NK Cell Neoplasms: A Global Retrospective Cohort Study

Mark N Sorial, Min Jung Koh, Leora Boussi, Jessy Xinyi Han, Luke Peng, Ijeoma Julie Eche-Ugwu, Rui Duan, Matthew M. Lei, Eliana Miranda, Carlos Chiattone, Robert Stuver, Steven M. Horwitz, Maria J. Fernandez Turizo, Sean McCabe, Mwanasha Hamuza Merrill, Eric Jacobsen, Jin Seok Kim, Yu Ri Kim, Jae Yong Cho, Hasmukh Jain, Manju Sengar, Thomas Eipe, Tanuja Shet, Shambhavi Singh, Uvette Lou, Hesham Raghib, Judith Gabler, Min Ji Koh, Carrie Van Der Weyden, Miles Prince, Ramzi Hamouche, Tinatin Muradashvili, Francine M. Foss, Marianna Gentilini, Beatrice Casadei, Pier Luigi Zinzani, Takeshi Okatani, Noriaki Yoshida, Sang Eun Yoon, Won Seog Kim, Girisha Panchoo, Zainab Mohamed, Estelle Verburgh, Jackielyn Cuenca Alturas, Mubarak Al Mansour, Josie Ford, Martina Manni, Massimo Federico, Owen A. O'Connor, Maria Elena Cabrera, Enrica Marchi, Changyu Shen, Devavrat Shah, Salvia Jain

Blood (2023) 142 (Supplement 1): 3080.

https://doi.org/10.1182/blood-2023-182341

Published: 2023

Journal Articles

Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era

Blood (2022) 140 (Supplement 1): 10976–10978.

https://doi.org/10.1182/blood-2022-162944

Published: 2022

Journal Articles

Significance of Soluble Interleukin-2 Receptor to Predict Prognosis and Support Decision-Making on Watchful Waiting for Stage II-IV Follicular Lymphoma Patients in the Rituximab Era

Tsuyoshi Muta, MD, Takeshi Okatani, MD, Mitsuhiro Itagaki, MD, Yoshimasa Suetsugu, MD, Masaaki Noda, MD, Tasuya Terasaki, MD, Yu Kochi, MD, Fumiaki Jinnouchi, MD, Tatsuji Mino, Ryota Imanaka, MD, Kohei Kyo, MD, Yuta Katayama, MD PhD, Shinya Katsutani, MD PhD, Koji Iwato, MD PhD, Hideki Asaoku, MD

Blood (2018) 132 (Supplement 1): 5321.

https://doi.org/10.1182/blood-2018-99-116016

Published: 2018

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Melphalan and Low-Dose Total Body Irradiation: A Single Center Analysis

Tatsuji Mino, Yuta Katayama, MD PhD, Tatsuya Terasaki, MD, Yu Kochi, MD, Fumiaki Jinnouchi, MD, Takeshi Okatani, MD, Ryota Imanaka, MD, Kohei Kyo, MD, Mitsuhiro Itagaki, MD, Shinya Katsutani, MD PhD, Tsuyoshi Muta, MD, Koji Iwato, MD PhD, Hideki Asaoku, MD

Blood (2018) 132 (Supplement 1): 2095.

https://doi.org/10.1182/blood-2018-99-113461

Published: 2018

Journal Articles

Therapy for AML with Myelodysplasia-Related Changes (AML-MRC)

Taiichi Kyo, MD, Kouhei Kyo, MD, Takeshi Okatani, MD, Tetsuro Ochi, MD, Kayo Toishigawa, Ryota Imanaka, MD, Yuta Katayama, MD PhD, Mitsuhiro Itagaki, MD

Blood (2015) 126 (23): 1340.

https://doi.org/10.1182/blood.V126.23.1340.1340

Published: 2015

Journal Articles

A High Incidence of Disseminated Intravascular Coagulation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Its Management

Ryota Imanaka, MD, Taiichi Kyo, MD, Kayo Toishigawa, MD, Tetsuro Ochi, MD, Takeshi Okatani, MD, Kouhei Kyo, MD, Mitsuhiro Itagaki, MD, Hisao Nagoshi, MD, Yuta Katayama, MD PhD, Koji Iwato, MD, Hideki Asaoku, MD

Blood (2015) 126 (23): 2500.

https://doi.org/10.1182/blood.V126.23.2500.2500

Published: 2015

Journal Articles

Deep Molecular Response Achieved By Second-Generation Tyrosine Kinase Inhibitors (TKIs) Can Lead to Stopping TKIs

Tetsuro Ochi, Taiichi Kyo, MD, Kayo Toishigawa, Takeshi Okatani, Ryota Imanaka, Kohei Kyo, Mitsuhiro Itagaki, Yuta Katayama, Koji Iwato, Hideki Asaoku

Blood (2015) 126 (23): 1594.

https://doi.org/10.1182/blood.V126.23.1594.1594

Published: 2015

Journal Articles

Title in Chemotherapy for Acute Myeloid Leukemia with High Leukocyte Counts.

Taiichi Kyo, MD, Ryota Imanaka, MD, Tetsuro Ochi, MD, Takeshi Okatani, MD, Kohei Kyo, MD, Mitsuhiro Itagaki, MD, Hisao Nagoshi, MD, Yuta Katayama, MD, Koji Iwato, MD, Hideki Asaoku, MD

Blood (2014) 124 (21): 5272.

https://doi.org/10.1182/blood.V124.21.5272.5272

Published: 2014

Journal Articles

Treatment of AML with Myelodysplasia Related Changes(AML-MRC) By Sequential Therapy of Azacitidine (AZA) and Intensive Chemotherapy

Taiichi Kyo, MD, Kouhei Kyo, MD, Kayo Toishikawa, MD, Ryota Imanaka, MD, Tetsuro Ochi, MD, Yuta Katayama, MD, Takeshi Okatani, MD, Mitsuhiro Itagaki, MD, Koji Iwato, MD, Hideki Asaoku, MD

Blood (2014) 124 (21): 5288.

https://doi.org/10.1182/blood.V124.21.5288.5288

Published: 2014

Journal Articles

Voriconazole (VRCZ) Versus Itraconazole (ITCZ) As Antifungal Prophylaxis For Acute Myelogenus Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients In Induction Therapy, Prospective Randomized Study

Kouhei Kyo, M.D., Mitsuhiro Itagaki, MD, Taiichi Kyo, MD, Takeshi Okatani, M.D., Tetsuro Ochi, Yuta Katayama, MD, PhD, Ryouta Imanaka, M.D., Kouji Iwato, Hideki Asaoku, M.D.

Blood (2013) 122 (21): 3897.

https://doi.org/10.1182/blood.V122.21.3897.3897

Published: 2013

Journal Articles

Improvement Of The Efficacy Of Azacitidine At a Fixed Dosing Schedule Of 75mg/m 2 /Day For 5 Days, Followed By 21 Days Drug-Off In Higher Risk Myelodysplastic Syndromes

Taiichi Kyo, M.D., Kouhei Kyo, MD, Ryouta Imanaka, M.D., Mitsuhiro Itagaki, MD, Tetsuro Ochi, Takeshi Okatani, M.D., Koji Iwato, MD, Yuta Katayama, MD, PhD, Hideki Asaoku, M.D.

Blood (2013) 122 (21): 1571.

https://doi.org/10.1182/blood.V122.21.1571.1571

Published: 2013

Journal Articles

Long-Term Outcome of All-Trans-Retinoic-Acid(ATRA)+Intensive Chemotherapy in Acute Promyelocytic Leukemia(APL),

Taiichi Kyo, M.D., Takeshi Okatani, M.D., Kouhei Kyo, M.D., Mitsuhiro Itagaki, M.D., Ryouta Imanaka, M.D., Koji Iwato, M.D., Hidkeki Asaoku, M.D., Yuuta Katayama, M.D.

Blood (2011) 118 (21): 3604.

https://doi.org/10.1182/blood.V118.21.3604.3604

Published: 2011

Journal Articles

Early Diagnostic Procedure and Treatment for Invasive Fungal Infection Centered on Invasive Aspergillosis in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia

Kouhei Kyo, M.D., Takeshi Okatani, M.D., Ryota Imanaka, M.D., Mitsuhiro Itagaki, M.D., Yuuta Katayama, M.D., Taiichi Kyo, M.D.

Blood (2011) 118 (21): 1544.

https://doi.org/10.1182/blood.V118.21.1544.1544

Published: 2011

Journal Articles

Results of Treatment with Tyrosine Kinase Inhibitors(TKIs) in Combination with Intensive Chemotherapy in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia(Ph+ALL)

Taiichi Kyo, M.D., Takeshi Okatani, M.D., Kouhei Kyo, Ryouta Imanaka, M.D., Mitsuhiro Itagaki, M.D., Yuuta Katayama, MD, Koji Iwato, M.D., Hideki Asaoku, MD

Blood (2011) 118 (21): 1503.

https://doi.org/10.1182/blood.V118.21.1503.1503

Published: 2011

Journal Articles

Treatment Results of Intensive Chemotherapy for Higher-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia Related to MDS (MDS-AML)

Taiichi Kyo, MD, Noriaki Yoshida, MD, Kouhei Kyo, MD, Takeshi Okatani, MD, Mitsuhiro Itagaki, MD, Hiromi Yuasa, MD, Koji Iwato, MD, Hideki Asaoku, MD, Yuuta Katayama, MD

Blood (2010) 116 (21): 2934.

https://doi.org/10.1182/blood.V116.21.2934.2934

Published: 2010

NARROW

Novel Causal Inference Method Estimates Treatment Effects of Contemporary Drugs in a Global Cohort of Patients with Relapsed and Refractory Mature T-Cell and NK-Cell Neoplasms

Impact of Therapy Sequence on Survival Outcomes Among Patients with Relapsed or Refractory Mature T and NK Cell Neoplasms: A Global Retrospective Cohort Study

Incorporation of Machine Learning Tools to Predict Global Outcomes for Patients with Relapsed and Refractory Peripheral T and NK/T-Cell Lymphomas in the Contemporary Era

Significance of Soluble Interleukin-2 Receptor to Predict Prognosis and Support Decision-Making on Watchful Waiting for Stage II-IV Follicular Lymphoma Patients in the Rituximab Era

Allogeneic Hematopoietic Stem Cell Transplantation Using Fludarabine/Melphalan and Low-Dose Total Body Irradiation: A Single Center Analysis

Therapy for AML with Myelodysplasia-Related Changes (AML-MRC)

A High Incidence of Disseminated Intravascular Coagulation in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia and Its Management

Deep Molecular Response Achieved By Second-Generation Tyrosine Kinase Inhibitors (TKIs) Can Lead to Stopping TKIs

Title in Chemotherapy for Acute Myeloid Leukemia with High Leukocyte Counts.

Treatment of AML with Myelodysplasia Related Changes(AML-MRC) By Sequential Therapy of Azacitidine (AZA) and Intensive Chemotherapy

Voriconazole (VRCZ) Versus Itraconazole (ITCZ) As Antifungal Prophylaxis For Acute Myelogenus Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) Patients In Induction Therapy, Prospective Randomized Study

Improvement Of The Efficacy Of Azacitidine At a Fixed Dosing Schedule Of 75mg/m 2 /Day For 5 Days, Followed By 21 Days Drug-Off In Higher Risk Myelodysplastic Syndromes

Long-Term Outcome of All-Trans-Retinoic-Acid(ATRA)+Intensive Chemotherapy in Acute Promyelocytic Leukemia(APL),

Early Diagnostic Procedure and Treatment for Invasive Fungal Infection Centered on Invasive Aspergillosis in Patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia

Results of Treatment with Tyrosine Kinase Inhibitors(TKIs) in Combination with Intensive Chemotherapy in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia(Ph+ALL)

Treatment Results of Intensive Chemotherapy for Higher-Risk Myelodysplastic Syndrome (HR-MDS) and Acute Myeloid Leukemia Related to MDS (MDS-AML)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only